Results of the Cox regression analyses to assess the association between BMI category and drug survival per TNFi within 1 year of follow-up
| Adjusted HR (95% CI) | P value | Crude HR (95% CI) | P value | |
|---|---|---|---|---|
| All TNFi | ||||
| BMI category | ||||
| Underweight | 1.37 (1.01; 1.86) | 0.044 | 1.30 (0.96; 1.77) | 0.085 |
| Normal weight | Ref | Ref | ||
| Pre-obesity | 0.85 (0.74; 0.99) | 0.038 | 0.89 (0.77; 1.03) | 0.126 |
| Obesity class I | 1.00 (0.83; 1.22) | 0.975 | 1.09 (0.90; 1.32) | 0.359 |
| Obesity class II | 1.14 (0.83; 1.57) | 0.408 | 1.25 (0.91; 1.71) | 0.163 |
| Obesity class III | 1.40 (0.92; 2.15) | 0.118 | 1.60 (1.05; 2.44) | 0.027 |
| Adalimumab | ||||
| BMI category | ||||
| Underweight | 1.58 (1.03; 2.42) | 0.037 | 1.41 (0.92; 2.14) | 0.112 |
| Normal weight | Ref | Ref | ||
| Pre-obesity | 0.67 (0.53; 0.85) | 0.001 | 0.72 (0.57; 0.90) | 0.003 |
| Obesity class I | 0.81 (0.60; 1.11) | 0.191 | 0.91 (0.67; 1.22) | 0.519 |
| Obesity class II | 0.91 (0.54; 1.55) | 0.733 | 1.01 (0.60; 1.71) | 0.958 |
| Obesity class III | 0.87 (0.43; 1.77) | 0.695 | 0.95 (0.47; 1.92) | 0.881 |
| Certolizumab | Number of patients per group too small | |||
| Etanercept | ||||
| BMI category | ||||
| Underweight | 0.99 (0.62; 1.59) | 0.976 | 1.04 (0.67; 1.61) | 0.862 |
| Normal weight | Ref | Ref | ||
| Pre-obesity | 1.05 (0.86; 1.27) | 0.653 | 1.04 (0.86; 1.25) | 0.714 |
| Obesity class I | 1.17 (0.90; 1.51) | 0.234 | 1.22 (0.96; 1.55) | 0.104 |
| Obesity class II | 1.64 (1.11); 2.42) | 0.014 | 1.51 (1.03; 2.22) | 0.034 |
| Obesity class III | 2.23 (1.33; 3.76) | 0.003 | 2.41 (1.46; 4.00) | 0.001 |
| Golimumab | Number of patients per group too small | |||
| Infliximab | ||||
| BMI category | ||||
| Underweight | 1.50 (0.78; 2.90) | 0.225 | 1.46 (0.78; 2.73) | 0.232 |
| Normal weight | Ref | Ref | ||
| Pre-obesity | 0.87 (0.63; 1.20) | 0.393 | 0.90 (0.66; 1.22) | 0.501 |
| Obesity class I | 1.21 (0.82; 1.78) | 0.338 | 1.29 (0.89; 1.87) | 0.172 |
| Obesity class II | 1.01 (0.48; 2.09) | 0.989 | 1.17 (0.59; 2.31) | 0.653 |
| Obesity class III | 1.74 (0.75; 4.07) | 0.199 | 2.16 (1.00; 4.64) | 0.049 |
Cox regression analyses results based on multiply imputed data. Adjusted analyses were corrected for gender, smoking, age, baseline DAS28 and GC use. Increased HR indicates a higher hazard to stop medication.
BMI, body mass index; DAS, disease activity score; GC, glucocorticoid; TNFi, tumour necrosis factor inhibitor.